在2型糖尿病中通过多草药配方进行快速和选择性肠道微生物组调节
Sintija Sauša1,2, Annija Zodāne3, Somit Kumar2
1Pauls Stradiņš Clinical University Hospital, Riga, Latvia.
Endocrine connections
|December 22, 2025
概括
这项研究表明,一种多草药配方可以改变2型糖尿病患者服用甲福林的肠道微生物群. 它增加了有益的Bifidobacterium,表明有可能改善甲胺耐受性.
科学领域:
- 微生物组研究的研究.
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 甲胺是2型糖尿病的第一线治疗方法,但会引起胃肠道副作用.
- 肠道微生物组会影响甲福明的疗效和耐受性.
- 这项研究调查了一种多草药配方对不耐美二型糖尿病患者肠道微生物群的影响.
研究的目的:
- 评估多草药配方作为对甲福明的补充疗法的影响,对肠道微生物群的组成和功能.
- 评估微生物多样性和特定细菌种群的变化.
- 探索潜在的针对微生物群的策略,以改善甲胺治疗.
主要方法:
- 这是一项为期7天的随机,安慰剂控制,交叉试验,涉及27名患有2型糖尿病的成年人.
- 参与者接受了多草药配方或安慰剂与甲福林.
- 便样本的枪支元基因组测序分析了微生物多样性,组成和通路.
主要成果:
- 没有观察到α-多样性的显著变化.
- 贝塔多样性显示了多草药和安慰剂组之间的显著差异.
- 多草药组表现出Bifidobacterium物种的丰富性增加和微生物通路的改变,而安慰剂组显示出最小的变化.
结论:
- 短期同时使用多草药配方可显著调节二型糖尿病患者的肠道微生物群.
- 该配方促进有益的种类,特别是Bifidobacterium.
- 这些发现支持多草药配方在针对微生物群的战略中发挥的潜在作用,以提高美特福林的耐受性和有效性.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
501
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
501
Oral Hypoglycemic Agents: Biguanides and Glitazones
559
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
559
Glucagon-like Receptor Agonists
816
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
816
Dipeptidyl Peptidase 4 Inhibitors
547
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
547
Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
What is Monogastric Digestion?
74.9K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
74.9K


